New York, October 8, 2026 / PRNewswire / -- Pomerantz LLP represents the investor investigation and related claims matters of ACADIA Pharmaceuticals Inc (referred to as " Acadia " or "the Company" ) ( NASDAQ : ACAD ). The law firm recommends that relevant investors contact Danielle Peyton, with the email address [ email protected ] and the phone number 646-581-9980, extension 7980.
This investigation involves whether Acadia and some of its senior executives and/or directors have engaged in securities fraud or other illegal business practices.
[Click here to learn how to join the class action.]
On September 24, 2026, Acadia issued a press release announcing the top-line results from the Phase II of the ongoing RADIANT clinical trial project, which is designed to evaluate the efficacy of remlifanserin in treating hallucinations and delusions associated with Alzheimer's disease psychosis ( ADP). Among the various data disclosed, the company stated that at a dose of 60 mg, remlifanserin "failed to meet" a key endpoint of a clinical tool used to measure the severity of the disease by a narrow margin.
Affected by this news, the stock price of Acadia fell by $3.25 per share on September 24, 2026, a decrease of 12.78%, closing at $22.18 per share.
Subsequently, on September 25, 2026, several analysts downgraded their ratings for Acadia on the grounds that the test results were disappointing.
Affected by this news, the stock price of Acadia fell by $1.50 per share on September 25, 2026, a decrease of 6.76%, closing at $20.68 per share.
Pomerantz LLP has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, and is considered one of the leading law firms in the fields of corporate, securities, and antitrust class actions. The firm was founded by the late Abraham L Pomerantz, who is regarded as a pioneer in the field of class action litigation. Pomerantz pioneered the field of securities class actions. More than 85 years later, Pomerantz continues this tradition, fighting for the rights of victims of securities fraud, breach of fiduciary duty, and corporate misconduct. The firm has secured millions of dollars in compensation for its class members. For more details, please refer to www.pomlaw.com.
Lawyer advertisement. Past results do not guarantee similar outcomes in the future.
Contact Information:
Danielle PeytonPomerantz LLP646-581-9980, extension 7980
